African Regulators to Establish Patient Safety Governance Framework at 2026 Summit

Africa’s medicines regulators and health institutions will convene in Kigali on September 16-17, 2026, for the inaugural Africa Patient Safety Summit, a gathering designed to produce binding governance commitments on one of the continent’s most consequential regulatory failures.

Medicines for Africa will host the Summit in partnership with the African Medicines Agency at the Kigali Convention Centre in Rwanda. The event marks a coordinated institutional response to medication-related harm stemming from substandard and falsified medicines, weak pharmacovigilance systems, and vulnerable supply chains.

The timing is deliberate. The African Medicines Agency’s establishment, accelerating regulatory harmonisation across member states, and rapid advances in digital health infrastructure have created an opening to strengthen medicines safety systems continent-wide. Yet emerging risks demand urgent coordination to ensure that medicines safety keeps pace with expanding pharmaceutical access.

The scale of the accountability gap is stark. The World Health Organization estimates that 10 to 30 percent of medicines in low- and middle-income countries may be substandard or falsified. Africa accounts for 42 percent of substandard and counterfeited medicines detected globally, and the global economic toll from such medicines exceeds US$200 billion annually. The human cost is more direct: an estimated one million people on the continent lose their lives to substandard and falsified medicines each year.

The WHO documented 70 children who died in The Gambia after receiving contaminated cough syrup, a case that illustrates precisely what happens when regulatory and safety systems fail to intercept dangerous products before they reach patients.

Evidence from formal and informal supply chains reinforces the urgency. A multi-country analysis spanning Kenya, Ethiopia, Cameroon and Malawi found that up to 20 percent of sampled cancer medicines were substandard or falsified, signalling a patient safety crisis that cuts across health system boundaries.

The Summit’s institutional architecture reflects the coordination required. Medicines for Africa will bring together regulators, governments, healthcare professionals, pharmaceutical manufacturers, researchers, digital health innovators, patient organisations and development partners under the theme “Advancing Patient Safety Through Collective Action to Prevent Medication-Related Harm.” Three strategic priorities will structure the agenda: preventing medication-related harm, strengthening patient-centred regulation, and driving coordinated action across Africa’s medicines ecosystem.

What changes the Summit is designed to produce are concrete governance instruments. Participants are expected to adopt a Kigali Declaration on Patient Safety and Medication-Related Harm, an Africa Roadmap for Preventing Medication-Related Harm, a Blueprint for Safer Medicines Use and Patient Protection, and a Continental Patient Safety Coordination Network. Each output is intended to give governments, regulators and health systems a framework for translating political commitment into coordinated continental action.

Medication-related harm, the Summit’s organisers stress, is not reducible to falsified products alone. Weak pharmacovigilance systems, poor market surveillance and fragile supply chains each contribute independently to preventable harm, treatment failure, antimicrobial resistance, avoidable healthcare costs and eroded public trust in health institutions. Addressing these systemic failures requires shared accountability across institutional and sectoral lines.

The underlying regulatory principle the Summit advances is unambiguous: medicines must not only be available across the continent; what is available must be safe, effective and trusted. Whether the governance instruments produced in Kigali translate into enforceable national commitments will be the measure by which the Summit is ultimately judged.